Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE versus REVEX.
NALOXONE vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
60-90 minutes in adults; shorter in neonates (3 hours); prolonged in hepatic impairment (up to 2-3 hours).
Clinical Note
moderateNaloxone + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Cyclosporine
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Renal: ~70% as metabolites (naloxone-3-glucuronide, naloxone-3-sulfate) and <2% unchanged; biliary/fecal: ~25% primarily as conjugated metabolites.
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist
"The metabolism of Cyclosporine can be decreased when combined with Naloxone."